Cargando…
Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis
Tyrosine kinase inhibitors (TKIs) were first approved for treating radioactive iodine-refractory differentiated thyroid cancer (DTC) and anaplastic thyroid cancer (ATC) 5 years ago. Among them, lenvatinib has a high response rate and has become the first-line drug for treating thyroid cancer. Althou...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783723/ https://www.ncbi.nlm.nih.gov/pubmed/33414909 http://dx.doi.org/10.3892/mco.2020.2190 |